Stewart A Factor

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint Primary progressive freezing gait: a syndrome with many causes
    Stewart A Factor
    Department of Neurology, Emory University School of Medicine, Atlanta, GA 30329, USA
    Neurology 66:411-4. 2006
  2. doi request reprint Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
    Stewart A Factor
    Emory University School of Medicine, Department of Neurology, Atlanta, Georgia 30329, USA
    Mov Disord 28:817-20. 2013
  3. doi request reprint Current status of symptomatic medical therapy in Parkinson's disease
    Stewart A Factor
    Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, Georgia 30329, USA
    Neurotherapeutics 5:164-80. 2008
  4. doi request reprint Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis
    Stewart A Factor
    Emory University School of Medicine, Department of Neurology, 1841 Clifton Road NE, Atlanta, GA 30329, USA
    J Neurol Neurosurg Psychiatry 82:564-8. 2011
  5. doi request reprint Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease
    Stewart A Factor
    Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA
    Mov Disord 26:2190-5. 2011
  6. ncbi request reprint Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia
    Stewart A Factor
    Parkinson s Disease and Movement Disorders Center of Albany Medical Center, Albany, New York, USA
    Mov Disord 20:1152-60. 2005
  7. ncbi request reprint Current and future treatments in multiple system atrophy
    Christine D Esper
    Stewart A Factor, DO Emory University School of Medicine, Wesley Woods Health Center, 1841 Clifton Road NE, Room 327, Atlanta, GA 30329, USA
    Curr Treat Options Neurol 9:210-23. 2007
  8. doi request reprint The clinical spectrum of freezing of gait in atypical parkinsonism
    Stewart A Factor
    Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    Mov Disord 23:S431-8. 2008
  9. doi request reprint Genetic association between alpha-synuclein and idiopathic Parkinson's disease
    Denise M Kay
    New York State Department of Health, Division of Genetic Disorders, Wadsworth Center, Albany, New York 12208, USA
    Am J Med Genet B Neuropsychiatr Genet 147:1222-30. 2008
  10. pmc Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease
    Haydeh Payami
    Genomics Institute, New York State Department of Health, Wadsworth Center, PO Box 22002, Albany, NY 12201 2002, USA
    Genet Epidemiol 34:92-9. 2010

Detail Information

Publications61

  1. ncbi request reprint Primary progressive freezing gait: a syndrome with many causes
    Stewart A Factor
    Department of Neurology, Emory University School of Medicine, Atlanta, GA 30329, USA
    Neurology 66:411-4. 2006
    ..PPFG is not a distinct disorder but a syndrome with diverse causes. Long-term follow-up (> or =10 years) and postmortem are required for accurate diagnosis. PNLD may be the primary form of disease...
  2. doi request reprint Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
    Stewart A Factor
    Emory University School of Medicine, Department of Neurology, Atlanta, Georgia 30329, USA
    Mov Disord 28:817-20. 2013
    ..Preladenant is a selective adenosine A₂A receptor antagonist under investigation for Parkinson's disease treatment...
  3. doi request reprint Current status of symptomatic medical therapy in Parkinson's disease
    Stewart A Factor
    Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, Georgia 30329, USA
    Neurotherapeutics 5:164-80. 2008
    ..The article closes with a discussion of future directions and new drugs under development...
  4. doi request reprint Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis
    Stewart A Factor
    Emory University School of Medicine, Department of Neurology, 1841 Clifton Road NE, Atlanta, GA 30329, USA
    J Neurol Neurosurg Psychiatry 82:564-8. 2011
    ..To test the hypothesis that postural instability with falling (PIF) and freezing of gait (FOG) are distinct subtypes of the postural instability/gait disturbance (PIGD) form of Parkinson's disease (PD)...
  5. doi request reprint Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease
    Stewart A Factor
    Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA
    Mov Disord 26:2190-5. 2011
    ..We demonstrated an association with depression and duration of disease, both of which were inconsistently related in previous studies, and confirmed the association with age, cognitive dysfunction, and sleep disorders...
  6. ncbi request reprint Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia
    Stewart A Factor
    Parkinson s Disease and Movement Disorders Center of Albany Medical Center, Albany, New York, USA
    Mov Disord 20:1152-60. 2005
    ..BoNT B therapy provides long-term benefit for CD patients but the magnitude of response diminishes over time. The cause of this decay is probably multifactorial. AR and NAR CD patients respond in a similar fashion...
  7. ncbi request reprint Current and future treatments in multiple system atrophy
    Christine D Esper
    Stewart A Factor, DO Emory University School of Medicine, Wesley Woods Health Center, 1841 Clifton Road NE, Room 327, Atlanta, GA 30329, USA
    Curr Treat Options Neurol 9:210-23. 2007
    ..The management for this disorder currently includes symptomatic and palliative strategies, as well as family education and support; the ultimate goal is to improve the quality of life for patients and their caregivers...
  8. doi request reprint The clinical spectrum of freezing of gait in atypical parkinsonism
    Stewart A Factor
    Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    Mov Disord 23:S431-8. 2008
    ..Both syndromes are heterogeneous but PSP seems to be the most common cause. CBD and DLB can also present as PPFG. FOG is a common feature of AP and although typically occurring late in disease may also be an early symptom...
  9. doi request reprint Genetic association between alpha-synuclein and idiopathic Parkinson's disease
    Denise M Kay
    New York State Department of Health, Division of Genetic Disorders, Wadsworth Center, Albany, New York 12208, USA
    Am J Med Genet B Neuropsychiatr Genet 147:1222-30. 2008
    ..1 for 261/261 to 59.4 +/- 11.5 for 257/257, displaying a trend of decreasing onset age with increasing allele size (P = 0.055). Genetic variation in SNCA and its regulatory regions play an important role in both familial and sporadic PD...
  10. pmc Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease
    Haydeh Payami
    Genomics Institute, New York State Department of Health, Wadsworth Center, PO Box 22002, Albany, NY 12201 2002, USA
    Genet Epidemiol 34:92-9. 2010
    ..MAP is intended as a descriptive method, to complement standard statistical techniques. Although originally developed for age patterns, MAP is equally useful for visualizing any quantitative trait...
  11. pmc Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease
    Taye H Hamza
    New York State Department of Health Wadsworth Center, Albany, New York, USA
    Nat Genet 42:781-5. 2010
    ..The genetic association with HLA supports the involvement of the immune system in Parkinson's disease and offers new targets for drug development...
  12. pmc Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class
    Donald L Bliwise
    Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA
    Mov Disord 27:1118-24. 2012
    ..The apparent divergent dose-dependent effects of drug class in Parkinson's disease are anticipated by basic science studies of the sleep/wake cycle under different pharmacological agents...
  13. ncbi request reprint Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease
    Denise M Kay
    Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
    Genet Test 10:221-7. 2006
    ..Test results can have psychological, social, and economical ramifications; thus, proper counseling is essential...
  14. pmc Association of Parkinson disease with structural and regulatory variants in the HLA region
    William T Wissemann
    Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA
    Am J Hum Genet 93:984-93. 2013
    ..Furthermore, our study demonstrates that noncoding SNPs in the HLA region can be associated with disease irrespective of HLA alleles, and that observed associations with HLA alleles can sometimes be secondary to a noncoding variant. ..
  15. pmc Evidence for more than one Parkinson's disease-associated variant within the HLA region
    Erin M Hill-Burns
    New York State Department of Health Wadsworth Center, Albany, New York, United States of America
    PLoS ONE 6:e27109. 2011
    ..60). Our findings suggest more than one PD-HLA association; either different alleles of the same gene, or separate loci...
  16. ncbi request reprint Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients
    Denise M Kay
    Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
    Ann Neurol 61:47-54. 2007
    ..We present a comprehensive sequence analysis of parkin in control subjects...
  17. pmc Sleep and impulsivity in Parkinson's disease
    Michael K Scullin
    Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA Electronic address
    Parkinsonism Relat Disord 19:991-4. 2013
    ..Previous research suggests a higher level of sleep complaints in PD patients who demonstrate impulsive behaviors, but the nature of the sleep disturbances has yet to be comprehensively tested...
  18. pmc Daytime REM sleep in Parkinson's disease
    Donald L Bliwise
    Department of Neurology, Emory University School of Medicine, Atlanta, GA 30329, USA
    Parkinsonism Relat Disord 19:101-3. 2013
    ..In this study we examined REM sleep during daytime Maintenance of Wakefulness Testing (MWT) in PD patients...
  19. pmc Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics
    Ann B Sollinger
    Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
    Parkinsonism Relat Disord 16:177-80. 2010
    ..Future studies should focus on additional risk factors for MCI subtypes and their possible progression to frank dementia...
  20. doi request reprint Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year interval
    Richard F Seegal
    Wadsworth Center, New York State Department of Health, Albany, NY 12201 0509, USA
    J Expo Sci Environ Epidemiol 21:234-46. 2011
    ..The results may aid in further understanding the toxicological/epidemiological consequences of exposure to PCBs in humans...
  21. ncbi request reprint Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics
    Denise M Kay
    Genomics Institute, Wadsworth Center, New York State Department of Health, Albany, 12201, USA
    Mov Disord 21:519-23. 2006
    ..Age at onset of mutation carriers ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date...
  22. pmc Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee
    Taye H Hamza
    New York State Department of Health Wadsworth Center, Albany, New York, USA
    PLoS Genet 7:e1002237. 2011
    ..GRIN2A may be a useful pharmacogenetic marker for subdividing individuals in clinical trials to determine which medications might work best for which patients...
  23. ncbi request reprint Threatening auditory hallucinations and Cotard syndrome in Parkinson disease
    Stewart A Factor
    Parkinson s Disease and Movement Disorders Center of Albany Medical Center, New York 12205, USA
    Clin Neuropharmacol 27:205-7. 2004
    ....
  24. pmc Cognitive and motor function in long-duration PARKIN-associated Parkinson disease
    Roy N Alcalay
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York2Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York
    JAMA Neurol 71:62-7. 2014
    ..Data on the long-term cognitive outcomes of patients with PARKIN-associated Parkinson disease (PD) are unknown but may be useful when counseling these patients...
  25. pmc Identification of a novel Parkinson's disease locus via stratified genome-wide association study
    Erin M Hill-Burns
    Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, NY, USA
    BMC Genomics 15:118. 2014
    ..The aim was to uncover new genes and gain insight into the genetic architecture of PD...
  26. ncbi request reprint Failure of recognition of drug-induced parkinsonism in the elderly
    Christine D Esper
    Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    Mov Disord 23:401-4. 2008
    ..Cessation of the offending agent results in improvement of symptoms and would eliminate the need for dopaminergic agents, which are known to commonly cause side effects in the elderly...
  27. ncbi request reprint The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia
    Sujana Reddy
    Department of Psychiatry, Albany Medical Center, Albany, New York 12205, USA
    Mov Disord 17:676-81. 2002
    ..We conclude that quetiapine is effective in improving psychosis in approximately 80% of PD patients both with and without dementia. Patients with dementia seem to have a higher propensity for worsening of motor symptoms...
  28. pmc Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa
    Yoland Smith
    Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, USA
    Neuropsychopharmacology 37:213-46. 2012
    ....
  29. doi request reprint Movement disorders emergencies Part 2: hyperkinetic disorders
    Bradley J Robottom
    Department of Neurology, University of Maryland School of Medicine, 110 S Paca St, 3 S 128, Baltimore, MD 21201, USA
    Arch Neurol 68:719-24. 2011
    ..Part 2 provides a diagnostic approach to the recognition and treatment of hyperkinetic movement disorders emergencies by identifying phenomenology and reviewing common etiologies...
  30. doi request reprint Movement disorders emergencies. Part 1: Hypokinetic disorders
    Bradley J Robottom
    Department of Neurology, University of Maryland School of Medicine, 110 S Paca Street, Baltimore, MD 21201, USA
    Arch Neurol 68:567-72. 2011
    ..Emergency complications related to the management of Parkinson disease, including falling, motor fluctuations, and psychiatric issues, will also be reviewed...
  31. ncbi request reprint Progressive supranuclear palsy
    Christine D Esper
    Department of Neurology Emory University School of Medicine, Atlanta, GA, USA
    Rev Neurol Dis 4:209-16. 2007
    ..Although there are no treatments that alter the natural history of disease in PSP and no drugs that provide significant symptomatic benefits, several supportive measures are available...
  32. ncbi request reprint Diabetes mellitus among parkinsonian patients treated chronically with clozapine
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL, USA
    Parkinsonism Relat Disord 10:439-41. 2004
    ..3% for ages > or = 60 years). In this small study, parkinsonian patients on long-term, low dose clozapine were not at increased risk for developing DM. Larger controlled prospective studies are needed to confirm this...
  33. doi request reprint Excessive daytime sleepiness in cervical dystonia
    Lynn Marie Trotti
    Emory University School of Medicine, Department of Neurology, Atlanta, GA 30329, USA
    Parkinsonism Relat Disord 15:784-6. 2009
    ..This preliminary finding of excessive daytime sleepiness in a substantial portion of CD patients suggests that further investigation into disordered sleep in CD is warranted...
  34. pmc Evidence of shared risk for Alzheimer's disease and Parkinson's disease using family history
    Ami R Rosen
    Department of Neurology, Emory University, 1841 Clifton Rd, Atlanta, GA 30329, USA
    Neurogenetics 8:263-70. 2007
    ..These findings suggest the existence of common genetic and/or environmental factors that predispose to both AD and PD in the subset of cases with positive family history of both neurodegenerative diseases...
  35. pmc Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging study
    Richard F Seegal
    Wadsworth Center, New York State Department of Health, Albany, NY 12201 0509, USA
    Neurobiol Dis 38:219-25. 2010
    ....
  36. ncbi request reprint Tardive dyskinesia
    Pratibha G Aia
    Department of Neurology, Emory University School of Medicine, 1841 Clifton Road, Atlanta, GA, 30329, USA
    Curr Treat Options Neurol 13:231-41. 2011
    ..This has the potential to worsen TD in the long run...
  37. ncbi request reprint Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy
    Christine D Esper
    Emory University School of Medicine, Department of Neurology, Movement Disorders Program, Atlanta, GA 30329, USA
    Parkinsonism Relat Disord 16:438-41. 2010
    ..We conclude that LPD is rare, most commonly the result of tardive and primary dystonia. Botulinum toxin therapy may be very effective but needs to be utilized with care because of the possibility for the development of dysphagia...
  38. ncbi request reprint Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease
    Stewart A Factor
    Parkinson s Disease and Movement Disorders Center of Albany Medical Center, Albany, New York 12205, USA
    Neurology 62:S12-7. 2004
    ..Subutaneous intermittent bolus injects are also useful in patients post operatively who are unable to take oral medications...
  39. ncbi request reprint The natural history of the syndrome of primary progressive freezing gait
    Stewart A Factor
    Parkinson s Disease and Movement Disorder Center of Albany Medical Center, 215 Washington Ave Extension, Albany, NY 12203, USA
    Arch Neurol 59:1778-83. 2002
    ..However, confusion remains about its clinical presentation, natural history, and classification...
  40. pmc A Neurodegenerative Disease Sleep Questionnaire: principal component analysis in Parkinson's disease
    Michael K Scullin
    Department of Neurology, Emory University School of Medicine, USA
    J Neurol Sci 336:243-6. 2014
    ..These results demonstrate construct validity of our sleep questionnaire and suggest that the NDSQ may be a useful screening tool for sleep disturbances in at least some types of neurodegenerative disorders. ..
  41. doi request reprint Seizures in juvenile Huntington's disease: frequency and characterization in a multicenter cohort
    Leslie J Cloud
    Department of Neurology, Virginia Commonwealth University, Richmond, Virginia 23298 0539, USA
    Mov Disord 27:1797-800. 2012
    ..Our ability to draw firm conclusions about defining EEG characteristics and response to AEDs was limited by the retrospective nature of the study. Future prospective studies are required...
  42. ncbi request reprint Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia
    Michael Silver
    Emory University School of Medicine, Department of Neurology, Wesley Woods Health Center, Atlanta, GA 30329, USA
    Parkinsonism Relat Disord 19:758-60. 2013
    ..While it is well known to cause postural tremor, hyperammonemia, slowness, and sedation, it has also been described to occasionally cause a reversible form of parkinsonism...
  43. pmc Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective
    Haydeh Payami
    New York State Department of Health, Division of Genetics, Wadsworth Center, Albany, NY, 12208, USA
    Neurotherapeutics 11:111-6. 2014
    ..In combination with known protective factors such as nicotine and caffeine, PGx may enable development of personalized methods for PD prevention and, by extension, care. ..
  44. pmc Tardive dyskinesia: therapeutic options for an increasingly common disorder
    Leslie J Cloud
    Department of Neurology, Emory University, 1841 Clifton Road NE, Atlanta, GA, 30329, USA
    Neurotherapeutics 11:166-76. 2014
    ....
  45. pmc Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment
    Gonzalo J Revuelta
    Department of Neurology, Division of Movement Disorders, Emory University School of Medicine, Atlanta, GA, USA
    Exp Neurol 237:464-9. 2012
    ..03). The unique features of FOG in PD can be replicated in severely parkinsonian macaques, and this represents the first description of a FOG animal model...
  46. ncbi request reprint Dystonia in AIDS: report of four cases
    Stewart A Factor
    Albany Medical Center, Department of Neurology, Albany, New York 12205, USA
    Mov Disord 18:1492-8. 2003
    ..When dystonia is seen in AIDS patients, its pattern may be a clue to the ultimate cause...
  47. ncbi request reprint Pharmacology of atypical antipsychotics
    Stewart A Factor
    Parkinson s Disease and Movement Disorder Center of Albany Medical Center, Albany, New York, USA
    Clin Neuropharmacol 25:153-7. 2002
  48. ncbi request reprint Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Mov Disord 17:158-61. 2002
    ..We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period...
  49. pmc Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease
    Carolyn M Hutter
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Eur J Neurol 15:134-9. 2008
    ..Our results suggest that UCHL1 S18Y is not a major susceptibility factor for PD in white populations although we cannot exclude the possibility that the S18Y variant exerts weak effects on risk, particularly in early-onset disease...
  50. ncbi request reprint Risperidone and Parkinson's disease
    Stewart A Factor
    Mov Disord 17:221-2. 2002
  51. ncbi request reprint Cervical dystonia in twins
    Stewart A Factor
    Mov Disord 17:846-7. 2002
  52. ncbi request reprint Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases
    Marjorie A Murphy
    Department of Ophthalmology, Rhode Island Hospital, Brown Medical School MAM, RI 02903, USA
    J Clin Neurosci 12:941-5. 2005
    ..We describe three cases diagnosed during life as PSP but found to have another neurologic disorder at autopsy. No explanation for the gaze palsies was found in any case...
  53. pmc LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago
    Cyrus P Zabetian
    Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
    Am J Hum Genet 79:752-8. 2006
    ..Our data suggest two separate founding events for G2019S in these populations, beginning at a time that coincides with the Jewish Diasporas...
  54. ncbi request reprint Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
    Joseph H Friedman
    Parkinson Disease and Movement Disorders Center, NeuroHealth, Warwick, Rhode Island 02886, USA
    Mov Disord 21:2078-81. 2006
    ..While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising...
  55. pmc Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study
    Alexis Elbaz
    INSERM, Unit 708, Paris, France
    Lancet Neurol 5:917-23. 2006
    ..Small-scale replication studies were largely non-confirmatory, but a meta-analysis that included data from the original study could not exclude all SNP associations, leaving relevance of several markers uncertain...
  56. ncbi request reprint Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation
    Stewart A Factor
    Mov Disord 22:148-9. 2007
  57. ncbi request reprint Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk
    Karen M Powers
    Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA
    Mov Disord 23:88-95. 2008
    ..13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated...
  58. pmc Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease
    Cyrus P Zabetian
    Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
    Ann Neurol 62:137-44. 2007
    ..We sought to replicate these findings...
  59. doi request reprint Exploring gene-environment interactions in Parkinson's disease
    Colin C McCulloch
    Applied Statistics Laboratory, General Electric Global Research Center, Niskayuna, NY, USA
    Hum Genet 123:257-65. 2008
    ..The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk...
  60. doi request reprint Advanced therapies for movement disorders in neurotherapeutics
    Mahlon R Delong
    Neurotherapeutics 5:163. 2008